Aequus Pharmaceuticals Inc. and Advanced Ophthalmic Innovations announced the signing of an exclusive distribution agreement for the PAUL® glaucoma drainage device in Canada. Under the terms of the agreement, AOI will supply the PAUL®? device and gain market authorization, and Aequus will be responsible for the marketing, distribution, sales, and supporting ongoing regulatory and market access activities.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.025 CAD | -16.67% |
|
-16.67% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 2.43M | |
+58.96% | 827B | |
+37.96% | 634B | |
-7.26% | 350B | |
+14.06% | 319B | |
+6.91% | 294B | |
+12.90% | 240B | |
+14.83% | 221B | |
+0.12% | 219B | |
+7.01% | 167B |
- Stock Market
- Equities
- AQS Stock
- News Aequus Pharmaceuticals Inc.
- Aequus Pharmaceuticals Inc. Signs Exclusive Distribution Agreement with Advanced Ophthalmic Innovations for the Paul® Glaucoma Drainage Device in Canada